Previous 10 | Next 10 |
Bank of America has opened a 90-day catalyst watch for Alnylam Pharmaceuticals as the RNAi therapeutics company plans to share topline data from a late-stage trial for experimental therapy patisiran in ATTR amyloidosis with cardiomyopathy (ATTR-CM). Patisiran is marketed as Onpattro in the U....
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals' (NASDAQ:ALNY) RNAi therapy Amvuttra (vutrisiran) to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The approval comes almost a month early from the date set by the FDA, afte...
– First and Only FDA-approved Treatment Demonstrating Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – AMVUTTRA Met Primary and All Secondary Endpoints, with Significant Improvement in Polyneuropathy, Quality o...
Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech focused on RNA interference, announced Thursday that its experimental RNAi therapy cemdisiran caused a 37% mean reduction of an important indicator of disease progression in immunoglobulin A nephropathy ((IgAN)). Alnylam (ALNY) has partnered wi...
- Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio , Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy - - Acceptable Safety Prof...
Brokerage William Blair on Tuesday initiated an outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, while estimating a fair value for the shares of $190, which represents a 44.3% upside to the stock's last closing price of $131.63. "The company has been led by a quality manageme...
Alnylam Pharmaceuticals (NASDAQ:ALNY) said new analysis from a late-stage study of its drug Oxlumo (lumasiran) showed that the drug helped improve cardiac measures, calcium deposit levels and kidney stone events in patients with advanced primary hyperoxaluria type 1 (PH1). PH1 is a ...
– Lumasiran Demonstrated Evidence of Improvements in Exploratory Endpoints of Systemic Oxalosis, Including Echocardiographic Structure and Function, Nephrocalcinosis, and Kidney Stone Events – – Expands Upon Previously Reported Reductions in Plasma Oxalate...
– New Exploratory Findings from 18-Month Analysis of HELIOS-A Suggest that Treatment with Investigational Vutrisiran May Benefit Patients with Hereditary ATTR (hATTR) Amyloidosis and Cardiac Involvement – – Improvements in NT-proBNP and Echocardiographic P...
Alnylam Pharmaceuticals (NASDAQ:ALNY) said Health Canada issued a notice of compliance (NOC) authorizing its Oxlumo (lumasiran) injection for subcutaneous use as a therapy for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adult patients. PH1 is a rare...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...